At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 309 enrolled
Drug / intervention
Zoster Vaccine, Live +1 morebiological
Likely dose
Zoster Vaccine, Live 0.65 mlfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase IIb Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of Zoster Vaccine Live (Oka/Merck) in Patients on Chronic/Maintenance Corticosteroids
In Brief
A Phase 2 clinical trial evaluating Zoster Vaccine, Live and Comparator: Placebo for Herpes Zoster. Completed, enrolled 309 participants.
Detailed Summary
The purpose of the study was to assess the safety, tolerability, and immunogenicity of ZOSTAVAX™ in patients receiving chronic/maintenance corticosteroids.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHerpes Zoster
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartOct 2007
First PostedOct 2007
Primary CompletionAug 2010
TodayJul 2026
First PostedOct 19, 2007
Enrollment StartOct 1, 2007
Primary CompletionAug 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 18.7 years ago
Interventions
Zoster Vaccine, Livebiological
A single dose of 0.65 ml Zoster Vaccine, Live, injected subcutaneously on Day 1
Comparator: Placebobiological
A single dose of 0.65 ml Placebo to ZOSTAVAX™ injected subcutaneously on Day 1.